TOPIC:

March 2016

The situation continues to favorable for importation of quality, affordable HCV medications into the United States.

Several options are available, most of which require a prescription. You can get that from GP2U.com. Get your lab results scanned and ready to send before your appointment.
(Genotype, viral load, CMP, CBC)
Your PCP or specialist can order those and give you a copy. Scan them and your U.S. Prescription if you have one.

Option 1: Join the REDEMPTION clinical trials. GP2U can assist you in that regard.

Option 2: Contact a legitimate supplier directly. Incepta seems to be the simplest as far as paperwork is concerned. Email This email address is being protected from spambots. You need JavaScript enabled to view it. for specific contact information.

Option 3: Become a "medical tourist" This is the most expensive option both in time and money, but still pennies on the dollar compared to the cost of branded U.S. Treatments.

Option 4: Fight your insurance company for coverage. Restrictions are easing, but time and effort is still required to negotiate the process. In all likelihood, you could be "cured" by generics before ever being approved for coverage by your insurer.

Mike

April Update:

To the best of my knowledge, the March update info is still accurate.
Although the TPP and presidential politics could change this situation at
ANY MOMENT!!
Take Australia's recent ban on imports from Bangladesh and Egypt, for example.: A bureaucrat's signature and a whole supply source is simply gone.
REDEMPTION, Incepta, MonkMed and Mesochem are still viable options in the U.S.
For how long?
Anyone's guess.
M

June 2016

The generic options in the U.S. are still viable. I would imagine Gilead is pouring money into the election campaigb coffers on both sudes of the aisle. See what they forced in Australia.
Get your medicine while you can.
m

The importation of generic HCV medications into the US continues to be a viable alternative to exorbitantly priced branded medicines, uncertain insurance coverage and long waits for treatment.
However, the political situation is fluid. Things could change.
Don't miss the opportunity to rid yourself of HCV in a cost-effective and timely manner.
m

May 2017 Update:
Given the political climate in the US I would not delay accessing these lifesaving, affordable generic HCV medications.
Contact GP2U.com. Set up an appointment and get well.
m

Hello to all visitors from the U.S. Please feel free to contact me at the email address below for answers concerning this site and how the generic treatment process works for U.S. citizens.
Mike

mgalbrai wrote: Hello to all visitors from the U.S. Please feel free to contact me at the email address below for answers concerning this site and how the generic treatment process works for U.S. citizens.
Mike

I second this gesture. Mike is an excellent person to contact. I recall a couple of years ago
a suggestion or two regarding a "sticky" section to highlight very important or frequently
asked questions that would benefit those who visited this website. It would be noted in red
or starred or whatever. I apologize in advance for not searching and might have missed the
answer why or there might be one.

In any case, it appears the urgency has dissipated....... Gilead is not the "bad" guy anymore,
pricing gouging comments have declined, uncaring USA GI doctors, etc. etc. etc.

Hep C is still alive and doing well here, unfortunately.

Mike is the man. Get in touch with him. Thanks , Mike, for your tireless efforts .

re_roll wrote:
In any case, it appears the urgency has dissipated....... Gilead is not the "bad" guy anymore,
pricing gouging comments have declined, uncaring USA GI doctors, etc. etc. etc.

I do not think Gilead is not "bad" anymore.... I would say they just suffer a side-effect of their high price policy and the fact that the healthcare systems do not afford to treat all patients and thus limit the access to treatments. If you look at Gilead's financial statements for 2017 you may see:
HCV product sales, which consist of Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg), Sovaldi® (sofosbuvir 400 mg), Epclusa® (sofosbuvir 400 mg/velpatasvir 100 mg) and Vosevi® (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg), were $1.5 billion for the fourth quarter of 2017 compared to $3.2 billion for the same period in 2016 and $9.1 billion for the full year 2017 compared to $14.8 billion in 2016. The declines were across all major markets.

So a drop of sales, but it is not clear whether they treated the same number of patients as in 2016.

According to a recent news available in my country, the government contracted a number of 12 000 treatments for the year 2017 (where it is estimated that more than 600 000 people have HCV), but managed to treat only 7 000 people. The treatment is provided to F3, F4 patients and the F2 patients having certain complications. This means a huge number of patients are not eligible to receive the treatment. In addition to this only few people know they have HCV and from those who know that are sick and do not meet the criteria for getting the free treatment, the solution of generic HCV drugs via parallel importation looks as a good option. Why wait till you got sicker to meet some stupid "access to treatment criteria" when you can get treated cheaper now?

P.S. I think we are getting tired in telling over and over that governments should remove the stupid access to treatment criteria and have a closer look to generic HCV medication.

Cheers,
RHF

Interesting statistics Rohcvfighter. I'm quite curious as to why Gilead's sales numbers have dropped so dramatically in 2017, the demand is still huge. Is it possibly because insurance only treats patients with severe fibrosis, and the number of these patients still left untreated is getting smaller year after year? I wonder what the real reason is.

Here are the approximate sales volumes (rather than financials) - they are accurate to +/- 10%



Up until 2016Q3 Gilead published their sales volumes (to analysts) but given the revenues from the drugs are known precisely (published by all the companies in their quarterly reports) we can calculate the yields. We also know precise pricing and volumes for some of the other drugs in other markets and relative pricing.

Anyway, the bottom line is that volumes between 2015Q2 and 2016Q1 at around 160,000 treatments per quarter and have now fallen globally to 80,000 treatments per quarter.

In short, we are losing the battle to eliminate HCV.